Calliditas Therapeutics AB (publ) (CALT)
- Previous Close
19.31 - Open
18.80 - Bid --
- Ask --
- Day's Range
18.67 - 20.38 - 52 Week Range
15.25 - 29.30 - Volume
5,987 - Avg. Volume
7,008 - Market Cap (intraday)
521.96M - Beta (5Y Monthly) 1.39
- PE Ratio (TTM)
-- - EPS (TTM)
-1.68 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
41.76
Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
www.calliditas.seRecent News: CALT
Performance Overview: CALT
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CALT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CALT
Valuation Measures
Market Cap
498.02M
Enterprise Value
497.36M
Trailing P/E
--
Forward P/E
769.23
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.68
Price/Book (mrq)
16.87
Enterprise Value/Revenue
0.41
Enterprise Value/EBITDA
-1.48
Financial Highlights
Profitability and Income Statement
Profit Margin
-38.63%
Return on Assets (ttm)
-12.23%
Return on Equity (ttm)
-84.68%
Revenue (ttm)
1.21B
Net Income Avi to Common (ttm)
-466.18M
Diluted EPS (ttm)
-1.68
Balance Sheet and Cash Flow
Total Cash (mrq)
973.73M
Total Debt/Equity (mrq)
288.70%
Levered Free Cash Flow (ttm)
-331.66M